Entering the era of computationally driven drug development

Area of Science:

• Pharmacology
• Drug Development
• Computational Chemistry

Background:

• Drug development exhibits persistently high attrition rates, with only 8% of new entities reaching regulatory approval.
• A key challenge is linking drug exposure to pharmacodynamic (PD) responses, often due to inadequate prediction of human outcomes by nonclinical models.
• This leads to inaccurate assessments of drug toxicology and efficacy, contributing to development failures.

Purpose of the Study:

• To address the high failure rates in drug development by improving the accuracy of preclinical predictions.
• To leverage advancements in computational methods and data standardization to enhance the prediction of pharmacokinetics (PK) and PD responses.
• To increase the probability of compound success in clinical trials through more reliable preclinical evaluations.

Main Methods:

• Utilizing improved quality and standardization of experimental methods in preclinical testing to generate valuable datasets.
• Applying computational models such as Quantitative Structure-Activity Relationships (QSAR) and physiologically based pharmacokinetics (PBPK).
• Integrating traditional computational techniques with machine learning approaches and internal pharmaceutical databases.

Main Results:

• Enhanced computational methods show potential for improving the efficiency and accuracy of preclinical predictions for PK and PD.
• These in silico approaches, grounded in biochemistry and xenobiotic interactions, can enhance the prediction of compound behavior in humans.
• The integration of diverse data and computational strategies promises to fundamentally impact prediction speed and accuracy.

Conclusions:

• Advancements in computational methods offer a promising avenue to mitigate high drug development failure rates.
• Improved in silico modeling and data integration can lead to more accurate preclinical assessments of drug safety and efficacy.
• This strategic integration has the potential to significantly accelerate and de-risk the drug development and approval process.